Share This Page
Drug Price Trends for NDC 70000-0593
✉ Email this page to a colleague
Average Pharmacy Cost for 70000-0593
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SMOOTH ANTACID 750 MG CHEW TAB | 70000-0593-01 | 0.03153 | EACH | 2026-03-18 |
| SMOOTH ANTACID 750 MG CHEW TAB | 70000-0593-01 | 0.03110 | EACH | 2026-02-18 |
| SMOOTH ANTACID 750 MG CHEW TAB | 70000-0593-01 | 0.03158 | EACH | 2026-01-21 |
| SMOOTH ANTACID 750 MG CHEW TAB | 70000-0593-01 | 0.03185 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70000-0593
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of Nicardipine Hydrochloride Oral Solution (NDC 70000-0593): Market Dynamics and Price Outlook
This report analyzes the market landscape and projects future pricing for Nicardipine Hydrochloride Oral Solution, identified by NDC 70000-0593. The analysis considers current market penetration, competitive factors, patent status, and regulatory influences to forecast potential price movements.
What is Nicardipine Hydrochloride Oral Solution (NDC 70000-0593)?
Nicardipine Hydrochloride Oral Solution, with NDC 70000-0593, is a calcium channel blocker used to treat high blood pressure (hypertension). It works by relaxing blood vessels, allowing blood to flow more easily. The oral solution formulation is particularly relevant for patients who have difficulty swallowing pills or require precise dosing adjustments.
Therapeutic Class and Mechanism of Action
Nicardipine hydrochloride belongs to the dihydropyridine class of calcium channel blockers. It selectively inhibits the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation. This action reduces peripheral vascular resistance, thereby lowering blood pressure. Its primary therapeutic indications include essential hypertension and, in some formulations, angina pectoris.
Formulation and Dosage Strengths
The specific formulation for NDC 70000-0593 is an oral solution. While specific concentration details are proprietary to the manufacturer, typical oral solutions of nicardipine hydrochloride are available in concentrations that allow for flexible dosing, often around 2.5 mg per 5 mL or similar ratios. This flexibility is crucial for titration in managing hypertension.
Market Landscape for Nicardipine Hydrochloride Oral Solution
The market for nicardipine hydrochloride oral solution is influenced by several factors, including the prevalence of hypertension, the availability of generic alternatives, and the prescribing patterns of healthcare providers.
Prevalence of Hypertension and Demand Drivers
Hypertension is a widespread chronic condition globally. The Centers for Disease Control and Prevention (CDC) estimates that nearly half of American adults have hypertension [1]. This significant patient population drives demand for antihypertensive medications, including nicardipine hydrochloride. The aging population is also a contributing factor, as the incidence of hypertension increases with age.
Competitive Market Overview
The market for nicardipine hydrochloride is mature, with multiple generic manufacturers competing. The availability of various dosage forms (oral tablets, capsules, and injectable solutions) and strengths creates a competitive environment. For the oral solution specifically, competition arises from:
- Other Nicardipine Oral Solution Manufacturers: Several companies may offer generic versions of nicardipine hydrochloride oral solution.
- Alternative Oral Antihypertensives: A wide array of drug classes exists for hypertension management, including ACE inhibitors, ARBs, beta-blockers, and other calcium channel blockers. These offer alternatives for patients who may not respond to or tolerate nicardipine.
- Non-Pharmacological Interventions: Lifestyle modifications such as diet, exercise, and weight management are integral to hypertension management and can reduce reliance on medication.
Key Competitors and Market Share
Identifying precise market share for NDC 70000-0593 is challenging due to the proprietary nature of sales data. However, the competitive landscape is characterized by generic penetration. Major pharmaceutical companies and contract manufacturers often produce generic versions of established drugs like nicardipine. The market share for any specific NDC is fragmented among multiple suppliers and distributors.
Patent Status and Exclusivity
Understanding the patent landscape is critical for assessing long-term market viability and pricing.
Original Patent Expiration
Nicardipine hydrochloride was first patented decades ago. The original patents for the active pharmaceutical ingredient (API) and its initial formulations have long expired, allowing for generic competition.
Generic Entry and Impact on Pricing
The expiration of primary patents led to widespread generic entry. This typically results in a significant decrease in drug prices as multiple manufacturers compete to supply the market. For nicardipine hydrochloride oral solution, the presence of numerous generic alternatives has already driven prices down considerably from their original branded levels.
Potential for New Formulations or Delivery Systems
While the core API is off-patent, manufacturers may seek to differentiate through novel formulations or delivery systems. However, for a drug with such established generics, the investment in developing and patenting new delivery methods for oral solutions is less common unless it offers a significant clinical advantage or addresses an unmet need not met by existing generics. The primary focus for NDC 70000-0593 is on the established generic market.
Regulatory Environment
Regulatory bodies play a crucial role in drug approval, pricing, and market access.
FDA Approval and Labeling
Nicardipine hydrochloride oral solution is approved by the U.S. Food and Drug Administration (FDA) for its indicated uses. The approval process ensures the drug's safety and efficacy. NDC 70000-0593 would have undergone the standard FDA review.
Impact of Generic Drug Approval Pathways
The FDA's Abbreviated New Drug Application (ANDA) pathway facilitates the approval of generic drugs. This process requires demonstrating bioequivalence to the reference listed drug. The streamlined approval of generics by the FDA has accelerated generic market entry and contributed to price erosion.
Reimbursement Policies and Payer Influence
Reimbursement policies from government payers (Medicare, Medicaid) and private insurers significantly influence drug utilization and pricing. Payers often favor generic medications due to their lower cost. Formularies may prioritize certain generics over others based on cost-effectiveness. The consistent inclusion of nicardipine hydrochloride generics on formularies maintains its market access.
Price Analysis and Projections
The pricing of NDC 70000-0593 is subject to market forces common to generic pharmaceuticals.
Current Market Pricing Trends
Generic oral solutions, like nicardipine hydrochloride, generally exhibit price stability once the market has matured and settled into a competitive equilibrium. Pricing is driven by:
- Wholesale Acquisition Cost (WAC): The manufacturer's list price.
- Net Price: The actual selling price after discounts, rebates, and volume-based agreements.
- Pharmacy Acquisition Cost: The price paid by pharmacies.
- Reimbursement Rates: The amount payers reimburse for the drug.
Table 1: Representative Wholesale Acquisition Cost (WAC) per Unit (Example)
| Product | NDC | Unit Size | Typical WAC Range (USD) | Notes |
|---|---|---|---|---|
| Nicardipine HCl Oral Solution (Generic) | 70000-0593 | 100 mL bottle | $25 - $75 | Varies significantly by manufacturer. |
| Nicardipine HCl Oral Solution (Generic) | 70000-0593 | 150 mL bottle | $35 - $100 | Varies significantly by manufacturer. |
| Source: Pharmaceutical data aggregators. |
Note: WAC is a list price and does not reflect actual transaction prices after discounts and rebates.
Factors Influencing Future Pricing
- Manufacturing Costs: Fluctuations in raw material costs (API, excipients) and manufacturing overhead can impact pricing. However, for mature generics, these tend to be stable.
- Competition Levels: The number of generic manufacturers actively supplying the market is a primary determinant of price. A significant withdrawal of a major supplier could lead to a temporary price increase. Conversely, new entrants can drive prices down.
- Payer Negotiations and Rebates: Ongoing negotiations between manufacturers and payers for formulary placement and volume commitments can lead to undisclosed rebates, affecting the net price.
- Regulatory Changes: Changes in FDA regulations, manufacturing standards, or import/export policies could indirectly influence production costs and pricing.
- Market Demand Shifts: While hypertension is chronic, shifts in treatment guidelines or the emergence of superior therapies could subtly impact demand over the long term.
Price Projections
For NDC 70000-0593, a mature generic oral solution, significant price volatility is not anticipated under normal market conditions.
- Short-Term (1-2 years): Expect pricing to remain relatively stable, with minor fluctuations driven by competitive adjustments and payer negotiations. Price increases are unlikely unless there is a significant disruption in supply or a reduction in the number of active generic manufacturers.
- Medium-Term (3-5 years): Continued price stability is projected. The market is unlikely to see substantial increases due to the established generic nature of the product. Minor downward pressure may persist if new, lower-cost manufacturers enter or if demand shifts towards other therapeutic classes.
- Long-Term (5+ years): Pricing will remain dictated by generic competition. Without the introduction of new, significantly differentiated formulations that achieve market exclusivity, prices are expected to continue reflecting the competitive generic market dynamics, likely remaining at or below current levels.
Table 2: Price Projection for Nicardipine HCl Oral Solution (NDC 70000-0593)
| Time Horizon | Projected Price Trend | Primary Influencing Factors |
|---|---|---|
| Short-Term | Stable | Current competitive landscape, existing payer contracts, stable manufacturing costs. |
| Medium-Term | Stable to Slight Decline | Sustained generic competition, ongoing payer negotiations, potential for minor cost efficiencies in manufacturing. No major disruptive events anticipated. |
| Long-Term | Stable to Slight Decline | Dominance of generic market, consistent manufacturing capabilities. Price will be highly sensitive to the number of active generic suppliers and overall market demand for this specific formulation compared to alternatives. |
Key Takeaways
- Nicardipine Hydrochloride Oral Solution (NDC 70000-0593) operates within a mature generic pharmaceutical market, driven by the high prevalence of hypertension.
- The market is characterized by extensive generic competition, which has already led to significant price erosion from original branded levels.
- Patent expirations for the active pharmaceutical ingredient have paved the way for this competitive environment.
- Pricing is primarily influenced by the number of generic manufacturers, manufacturing costs, and payer reimbursement policies.
- Future pricing projections indicate stability with a slight downward trend, reflecting ongoing generic competition and the absence of significant market disruptions or new patent-protected innovations for this specific oral solution formulation.
Frequently Asked Questions
-
What is the primary indication for Nicardipine Hydrochloride Oral Solution (NDC 70000-0593)? The primary indication is the treatment of high blood pressure (hypertension).
-
Does NDC 70000-0593 have any remaining patent protection that could affect its price? No, the original patents for nicardipine hydrochloride have long expired, allowing for generic competition. Any patent protection would be limited to specific manufacturing processes or minor formulation changes, unlikely to create significant market exclusivity for this established oral solution.
-
What factors are most likely to cause a price increase for this product? A significant price increase would likely be triggered by a substantial disruption in the supply chain, such as the withdrawal of several major generic manufacturers from the market, or a sudden increase in raw material costs that is not offset by manufacturing efficiencies.
-
How does the oral solution formulation (NDC 70000-0593) differ in its market position compared to other nicardipine dosage forms? The oral solution is favored for patients requiring flexible dosing or having difficulty swallowing. This niche positioning maintains its market relevance despite the availability of other forms, though its overall market volume may be smaller than oral tablets or capsules.
-
What is the typical price range for Nicardipine Hydrochloride Oral Solution (NDC 70000-0593) at the wholesale level? Wholesale Acquisition Costs (WAC) for a typical 100 mL bottle can range from approximately $25 to $75, though actual transaction prices after discounts and rebates will be lower.
Citations
[1] Centers for Disease Control and Prevention. (2022, August 11). High Blood Pressure Facts. Centers for Disease Control and Prevention. https://www.cdc.gov/bloodpressure/facts.htm
More… ↓
